Product Information
PROGLYCEM 50 MG/ML ORAL SUSP is a brand product labeled by Teva Pharmaceuticals USA Inc., priced at $16.7058 per ML under NDC 00575620030. Its NADAC has been published 458 times since Nov 28, 2013.
Strength
50 mg/mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00575620030
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
DIAZOXIDEApproval Type
New Drug (NDA)
FDA Application
NDA017453On Market Since
9/30/1990
Price Statistics
The NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has been published 458 times since Nov 28, 2013, and over the history we have for it it has risen 139.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $16.7058 per ML |
|---|---|
| All-time high | $16.9362 (May 13, 2026) |
| All-time low | $6.9693 (Nov 28, 2013) |
| 52-week high | $16.9362 |
| 52-week low | $15.2953 |
| Median price | $10.2519 |
| Average price | $10.7454 |
| Largest weekly change | +27.9% (Jul 17, 2024) |
| Weeks tracked | 458 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 59% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of PROGLYCEM 50 MG/ML ORAL SUSP?
The current National Average Drug Acquisition Cost (NADAC) for PROGLYCEM 50 MG/ML ORAL SUSP, manufactured by Teva Pharmaceuticals USA Inc., is $16.7058 per ML (NDC 00575620030), effective Jun 24, 2026.
How has the price of PROGLYCEM 50 MG/ML ORAL SUSP changed over time?
Over the history we have for it, the NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has risen 139.7%. It has been tracked across 458 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PROGLYCEM 50 MG/ML ORAL SUSP?
Since Nov 28, 2013, the NADAC for PROGLYCEM 50 MG/ML ORAL SUSP has ranged from a low of $6.9693 (Nov 28, 2013) to a high of $16.9362 (May 13, 2026), with a median of $10.2519 per ML.
Are there cheaper alternatives to PROGLYCEM 50 MG/ML ORAL SUSP?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, DIAZOXIDE 50 MG/ML ORAL SUSP, is $6.8307 per ML — about 59% below PROGLYCEM 50 MG/ML ORAL SUSP.
Who manufactures PROGLYCEM 50 MG/ML ORAL SUSP?
PROGLYCEM 50 MG/ML ORAL SUSP (NDC 00575620030) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification